{
  "id": 10078384,
  "title": "Europe Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccines",
  "url": "https://urgent.news/2026/09/26/europe-injects-capital-into-colombian-biotech-firm-to-produce-250",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-26T22:31:00.000Z",
  "source": {
    "name": "Colombia One",
    "slug": "colombia-one",
    "url": "https://colombiaone.com/2026/09/26/europe-injects-capital-into-colombian-biotech-firm-to-produce-250-million-vaccines/"
  },
  "original_language": "en",
  "account": "The European Investment Bank (EIB) has provided a 15 million euro venture debt loan to Colombia's VaxThera biotech firm, which is focused on developing, manufacturing, and commercializing vaccines and biopharmaceutical products. This financing is part of an overarching 35 million euro package approved for VaxThera's second phase integrated plant for vaccine production, capable of manufacturing up to 250 million doses annually. The loan will support the construction, fitting-out, and validation of this large-scale plant, enhancing VaxThera's ability to produce vaccines and provide contract manufacturing services for other biological products. This investment, announced in New York within the framework of the 81st United Nations General Assembly, aims to bolster Colombia's vaccine research and manufacturing capacity, improve regional access to vaccines, and strengthen the resilience of supply chains, particularly in the face of potential health emergencies. The European Commission is also providing technical assistance worth 1.5 million euros for VaxThera's research and development of three candidate vaccines against infectious diseases of regional and global importance. This initiative, part of the European Union's Global Gateway strategy, supports healthcare systems, R&D, and skills development in Latin America, while reducing the country's dependence on imported vaccines and biological medicines.",
  "summary": "The European Investment Bank (EIB), in collaboration with the European Commission, the politically independent executive body of the European Union responsible for proposing legislation, implementing policies and managing the EU budget, will grant a 15 million euro (US$17 million) venture debt loan to a Colombian biotechnology company dedicated to the development, manufacture and…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}